Headquarters

Eveliqure Biotechnologies GmbH

Campus Vienna Biocenter


Karl-Farkas-Gasse 22

A-1030 Vienna

Austria

  • White Facebook Icon
  • White LinkedIn Icon

© 2019 Eveliqure Biotechnologies GmbH

How it works

The proprietary Eveliqure vaccine technology platform is based on a live attenuated Shigella vaccine strain able to induce broad protection against shigellosis due to targeted genetic mutations   These unique characteristics are due to specific mutations introduced into the Shigella strain: deletion of the serotype-determining LPS O-antigen results in an increased immune response to shared minor antigens, and inactivation of the type III secretion system  renders the vaccine strain non-invasive. Additionally, a third deletion inactivates a putative enterotoxin in order to further improve the safety profile of the vaccine strain. Eveliqure has increased the stability of the vaccine strain by transposition of an essential gene from the chromosome to the Shigella's invasion plasmid to ensure heterologous antigens are retained and there is no reversion of the attenuating mutations.

The first product candidate, ShigETEC expresses a tandem repeat of a  fusion protein of LTB and an ST toxoid that induces neutralizing antibodies and thus protective immunity against both toxins of ETEC strains.

 Conserved Minor Antigens

Coat

LPS O - ANTIGEN STRUCTURE

highly immunogenic 
but high variability  (serotype determinant)

Conserved Minor Antigens

CONSERVED MINOR ANTIGENS

usually neglected by the immune system since masked by the bulk LPS antigen

DIFFERENT COAT, SAME CONSERVED MINOR ANTIGENS

4 species and many serotypes

Shigella dysenteriae

(15 serotypes)

Shigella flexneri (19 serotypes)

Shigella boydii

(19 serotypes)

Shigella sonnei

(1 serotype)

ANTIBODY RESPONSE AGAINST SHIGELLA

INDUCED BY THE OUTER LPS-ANTIGEN “COAT”

Dominant antibody response against the serotype determinant O-antigens

EVELIQURE APPROACH: REMOVAL OF THE COAT LEADS TO BROAD, SEROTYPE INDEPENDENT ANTIBODY RESPONSE

Minor antigens that were previously hidden are exposed to trigger a more robust immune response that mediate cross protection (vaccine strain without LPS O-antigen)